HRP20241675T1 - Primjena prolijekova riluzola za liječenje ataksija - Google Patents
Primjena prolijekova riluzola za liječenje ataksija Download PDFInfo
- Publication number
- HRP20241675T1 HRP20241675T1 HRP20241675TT HRP20241675T HRP20241675T1 HR P20241675 T1 HRP20241675 T1 HR P20241675T1 HR P20241675T T HRP20241675T T HR P20241675TT HR P20241675 T HRP20241675 T HR P20241675T HR P20241675 T1 HRP20241675 T1 HR P20241675T1
- Authority
- HR
- Croatia
- Prior art keywords
- ataxia
- riluzole
- prodrug
- ch2ch3
- following formula
- Prior art date
Links
- 206010003591 Ataxia Diseases 0.000 title claims 9
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 title claims 9
- 239000000651 prodrug Substances 0.000 title claims 9
- 229940002612 prodrug Drugs 0.000 title claims 9
- 229960004181 riluzole Drugs 0.000 title claims 9
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 102000007372 Ataxin-1 Human genes 0.000 claims 2
- 108010032963 Ataxin-1 Proteins 0.000 claims 2
- 102000014461 Ataxins Human genes 0.000 claims 2
- 108010078286 Ataxins Proteins 0.000 claims 2
- -1 CH2CCH Chemical group 0.000 claims 2
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 claims 2
- 108091026890 Coding region Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762584856P | 2017-11-12 | 2017-11-12 | |
| US201862717948P | 2018-08-13 | 2018-08-13 | |
| PCT/US2018/060232 WO2019094851A1 (en) | 2017-11-12 | 2018-11-11 | Use of riluzole prodrugs to treat ataxias |
| EP18876779.2A EP3706739B1 (en) | 2017-11-12 | 2018-11-11 | Use of riluzole prodrugs to treat ataxias |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20241675T1 true HRP20241675T1 (hr) | 2025-02-14 |
Family
ID=66438598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20241675TT HRP20241675T1 (hr) | 2017-11-12 | 2018-11-11 | Primjena prolijekova riluzola za liječenje ataksija |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20210023061A1 (https=) |
| EP (4) | EP4483956B1 (https=) |
| JP (2) | JP7352542B2 (https=) |
| KR (2) | KR20200103658A (https=) |
| CN (1) | CN112292127A (https=) |
| AU (1) | AU2018364749C1 (https=) |
| BR (1) | BR112020009173A2 (https=) |
| CA (1) | CA3082096A1 (https=) |
| DK (2) | DK3706739T3 (https=) |
| ES (1) | ES2996892T3 (https=) |
| FI (2) | FI3706739T3 (https=) |
| HR (1) | HRP20241675T1 (https=) |
| HU (1) | HUE070302T2 (https=) |
| IL (1) | IL274532B2 (https=) |
| LT (2) | LT3706739T (https=) |
| MD (1) | MD3706739T2 (https=) |
| MX (2) | MX2020004678A (https=) |
| PH (1) | PH12020550583A1 (https=) |
| PL (1) | PL3706739T3 (https=) |
| PT (2) | PT3706739T (https=) |
| RS (1) | RS66277B1 (https=) |
| SG (1) | SG11202004332XA (https=) |
| SI (1) | SI3706739T1 (https=) |
| SM (1) | SMT202500022T1 (https=) |
| WO (1) | WO2019094851A1 (https=) |
| ZA (1) | ZA202002626B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016140879A1 (en) | 2015-03-03 | 2016-09-09 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzole prodrugs and their use |
| US12295942B2 (en) | 2015-03-03 | 2025-05-13 | Biohaven Therapeutics Ltd. | Riluzole prodrugs and their use |
| WO2018031707A1 (en) | 2016-08-10 | 2018-02-15 | Biohaven Pharmaceutical Holding Company Ltd. | Acyl benzo[d]thiazol-2-amine and their methods of use |
| EP4277624B1 (en) * | 2021-01-18 | 2026-01-14 | Biohaven Therapeutics Ltd. | Troriluzole for use in the treatment of alzheimer's disease of mild severity |
| US20250127789A1 (en) * | 2021-11-04 | 2025-04-24 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
| WO2023230451A2 (en) * | 2022-05-23 | 2023-11-30 | Biohaven Therapeutics Ltd. | Methods of treating spinocerebellar ataxias |
| WO2026078657A1 (en) | 2024-10-10 | 2026-04-16 | Biohaven Therapeutics Ltd. | Prodrugs of riluzole |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| ATE208615T1 (de) | 1993-07-09 | 2001-11-15 | Scherer Corp R P | Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen |
| US5457895A (en) | 1993-10-01 | 1995-10-17 | R. P. Scherer Corporation | Method of identifying freeze-dried dosage forms |
| US5837287A (en) | 1994-10-28 | 1998-11-17 | R P Scherer Corporation | Process for preparing solid pharmaceutical dosage forms |
| WO1998036738A1 (en) | 1997-02-20 | 1998-08-27 | Therics, Inc. | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same |
| PT1001748E (pt) | 1997-07-25 | 2006-08-31 | Alpex Pharma Sa | Um processo para a preparacao de um granulado adequado para a preparacao de comprimidos rapidamente desintegraveis na boca |
| FR2774592B1 (fr) * | 1998-02-06 | 2000-03-17 | Rhone Poulenc Rorer Sa | Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet |
| IL143197A0 (en) | 1998-11-20 | 2002-04-21 | Rtp Pharma Inc | Dispersible phospholipid stabilized microparticles |
| GB9908014D0 (en) | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| US6284270B1 (en) | 1999-08-04 | 2001-09-04 | Drugtech Corporation | Means for creating a mass having structural integrity |
| US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| US6814978B2 (en) | 2000-12-29 | 2004-11-09 | Mcneil-Ppc, Inc. | Process for preparing a soft tablet |
| US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
| ES2292848T3 (es) | 2001-10-12 | 2008-03-16 | Elan Pharma International Limited | Composiciones que tienen una combinacion de caracteristicas de liberacion inmediata y liberacion controlada. |
| AU2003211051A1 (en) | 2002-02-13 | 2003-09-04 | Michael K. Weibel | Drug dose-form and method of manufacture |
| ATE337003T1 (de) * | 2003-04-28 | 2006-09-15 | Biofrontera Bioscience Gmbh | Verwendung von riluzole kombiniert mit geeigneten hilfs-und zusatzstoffen zur behandlung von krankheiten, die durch eine hyperproliferation von keratinozyten gekennzeichnet sind, insbesondere neurodermitis und psoriasis |
| US7282217B1 (en) | 2003-08-29 | 2007-10-16 | Kv Pharmaceutical Company | Rapidly disintegrable tablets |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| BRPI0620578A2 (pt) | 2005-12-27 | 2011-12-06 | Jubilant Organosys Ltd | composição farmacêutica que dissolve na boca e processo para o preparo da mesma |
| EP2170282A4 (en) | 2007-06-27 | 2014-11-05 | Hanmi Pharm Ind Co Ltd | METHOD FOR PRODUCING A QUICKLY CRUSHING FORMULATION FOR ORAL ADMINISTRATION AND DEVICE FOR PREPARING AND PACKAGING THE FORMULATION |
| WO2009146031A1 (en) * | 2008-03-31 | 2009-12-03 | University Of South Florida | Methods of treating disease-induced ataxia and non-ataxic imbalance |
| US8414356B2 (en) | 2008-10-31 | 2013-04-09 | The Invention Science Fund I, Llc | Systems, devices, and methods for making or administering frozen particles |
| US8613937B2 (en) | 2008-10-31 | 2013-12-24 | The Invention Science Fund I, Llc | Compositions and methods for biological remodeling with frozen particle compositions |
| US8313768B2 (en) | 2009-09-24 | 2012-11-20 | Mcneil-Ppc, Inc. | Manufacture of tablet having immediate release region and sustained release region |
| WO2016140879A1 (en) * | 2015-03-03 | 2016-09-09 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzole prodrugs and their use |
-
2018
- 2018-11-11 EP EP24199849.1A patent/EP4483956B1/en active Active
- 2018-11-11 IL IL274532A patent/IL274532B2/en unknown
- 2018-11-11 MD MDE20200953T patent/MD3706739T2/ro unknown
- 2018-11-11 PL PL18876779.2T patent/PL3706739T3/pl unknown
- 2018-11-11 EP EP25216894.3A patent/EP4696324A3/en active Pending
- 2018-11-11 KR KR1020207016775A patent/KR20200103658A/ko not_active Ceased
- 2018-11-11 EP EP25216909.9A patent/EP4699619A3/en active Pending
- 2018-11-11 DK DK18876779.2T patent/DK3706739T3/da active
- 2018-11-11 LT LTEPPCT/US2018/060232T patent/LT3706739T/lt unknown
- 2018-11-11 DK DK24199849.1T patent/DK4483956T3/da active
- 2018-11-11 CN CN201880073828.6A patent/CN112292127A/zh active Pending
- 2018-11-11 MX MX2020004678A patent/MX2020004678A/es unknown
- 2018-11-11 BR BR112020009173-1A patent/BR112020009173A2/pt not_active Application Discontinuation
- 2018-11-11 HR HRP20241675TT patent/HRP20241675T1/hr unknown
- 2018-11-11 AU AU2018364749A patent/AU2018364749C1/en active Active
- 2018-11-11 SM SM20250022T patent/SMT202500022T1/it unknown
- 2018-11-11 US US16/762,165 patent/US20210023061A1/en active Pending
- 2018-11-11 SI SI201831180T patent/SI3706739T1/sl unknown
- 2018-11-11 LT LTEP24199849.1T patent/LT4483956T/lt unknown
- 2018-11-11 WO PCT/US2018/060232 patent/WO2019094851A1/en not_active Ceased
- 2018-11-11 FI FIEP18876779.2T patent/FI3706739T3/fi active
- 2018-11-11 PT PT188767792T patent/PT3706739T/pt unknown
- 2018-11-11 CA CA3082096A patent/CA3082096A1/en active Pending
- 2018-11-11 KR KR1020257006278A patent/KR20250034521A/ko active Pending
- 2018-11-11 PT PT241998491T patent/PT4483956T/pt unknown
- 2018-11-11 FI FIEP24199849.1T patent/FI4483956T3/fi active
- 2018-11-11 RS RS20241371A patent/RS66277B1/sr unknown
- 2018-11-11 SG SG11202004332XA patent/SG11202004332XA/en unknown
- 2018-11-11 ES ES18876779T patent/ES2996892T3/es active Active
- 2018-11-11 JP JP2020526149A patent/JP7352542B2/ja active Active
- 2018-11-11 HU HUE18876779A patent/HUE070302T2/hu unknown
- 2018-11-11 EP EP18876779.2A patent/EP3706739B1/en active Active
-
2020
- 2020-05-08 PH PH12020550583A patent/PH12020550583A1/en unknown
- 2020-05-11 ZA ZA2020/02626A patent/ZA202002626B/en unknown
- 2020-07-13 MX MX2023012640A patent/MX2023012640A/es unknown
-
2023
- 2023-07-17 US US18/353,840 patent/US12102618B2/en active Active
- 2023-07-17 US US18/353,850 patent/US20230355592A1/en active Pending
- 2023-09-15 JP JP2023149803A patent/JP2023175823A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20241675T1 (hr) | Primjena prolijekova riluzola za liječenje ataksija | |
| ATE511392T1 (de) | Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit | |
| HRP20220237T1 (hr) | Primjena riluzola, prolijekova riluzola ili analoga riluzola sa imunoterapijama za liječenje raka | |
| JP1732770S (ja) | 筋膜リリースマッサージガンのマッサージヘッド | |
| JP1732772S (ja) | 筋膜リリースマッサージガンのマッサージヘッド | |
| AR062401A1 (es) | Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis | |
| ZA202006072B (en) | Ret inhibitor for use in treating cancer having a ret alteration | |
| JP1732773S (ja) | 筋膜リリースマッサージガンのマッサージヘッド | |
| JP1732769S (ja) | 筋膜リリースマッサージガンのマッサージヘッド | |
| AR062393A1 (es) | Uso de derivado del 2.5-dihidrixibenceno para el tratamiento de artritis y dolor | |
| MX2024010655A (es) | Uso de profarmacos de riluzol para tratar enfermedad de alzheimer. | |
| EP3781584A4 (en) | 4'-THIO-NUCLEOTIDE AND NUCLEOSIDE PRODRUGS FOR THE TREATMENT OF CANCER | |
| JP1747435S (ja) | 筋膜リリースマッサージガンのマッサージヘッド | |
| JP1747437S (ja) | 筋膜リリースマッサージガンのマッサージヘッド | |
| MX2024007642A (es) | Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades. | |
| EA202092361A1 (ru) | Конъюгат цитотоксического лекарственного средства и пролекарственная форма указанного конъюгата | |
| TWD209212S (zh) | 可拆卸牙刷頭 | |
| MX2023010506A (es) | Composiciones que comprenden profarmacos de escision enzimatica y nafamostat de liberacion controlada y metodos de uso de estos. | |
| MX2019001412A (es) | Compuestos de 9-aminometil minociclina y usos de los mismos. | |
| BR112021017198A2 (pt) | Uso de vibegron para tratar bexiga hiperativa | |
| JP1725166S (ja) | 歯列矯正器具 | |
| EP4297590A4 (en) | Oral dose compositions of tributyrin for the therapeutic generation of butyrate in the gut | |
| HRP20171532T1 (hr) | Apoekvorin za smanjenje neuronalne ozljede uvjetovane ishemijom | |
| EP3853225A4 (en) | NOVEL THIAZOLE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | |
| EP4355326A4 (en) | THERAPEUTICALLY EFFECTIVE ORAL ADMINISTRATION OF A 2-ARYL-BENZIMIDAZOLE |